What is HC Wainwright’s Forecast for ACRV FY2030 Earnings?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Equities researchers at HC Wainwright raised their FY2030 EPS estimates for shares of Acrivon Therapeutics in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn $0.14 per share for the year, up from their prior forecast of $0.13. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($1.92) per share.

Acrivon Therapeutics (NASDAQ:ACRV) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.07.

Separately, Weiss Ratings lowered Acrivon Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $13.50.

Acrivon Therapeutics Stock Up 7.6%

Shares of NASDAQ ACRV opened at $1.85 on Friday. The firm’s 50-day moving average price is $1.67 and its two-hundred day moving average price is $1.68. Acrivon Therapeutics has a 52-week low of $1.26 and a 52-week high of $3.56. The stock has a market capitalization of $79.18 million, a P/E ratio of -0.98 and a beta of 1.85.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its holdings in Acrivon Therapeutics by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 198,223 shares of the company’s stock worth $478,000 after purchasing an additional 6,190 shares during the period. Renaissance Technologies LLC raised its position in shares of Acrivon Therapeutics by 1.7% during the 4th quarter. Renaissance Technologies LLC now owns 634,169 shares of the company’s stock worth $1,528,000 after buying an additional 10,769 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Acrivon Therapeutics in the 4th quarter worth approximately $40,000. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Acrivon Therapeutics during the fourth quarter valued at approximately $44,000. Finally, Focus Partners Wealth bought a new stake in Acrivon Therapeutics during the third quarter worth approximately $36,000. 71.62% of the stock is currently owned by institutional investors.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.